http://www.jvir.org/, https://www.instagram.com/jvirmedia/, http://www.youtube.com/watch?v=rRBQ9trQ7co, https://twitter.

Journal of Vascular and Interventional Radiology, 1600 John F Kennedy Blvd, Philadelphia, PA (2025)

09/09/2025

**NEW IN JVIR:** Magnetic Resonance Imaging-guided Transurethral Ultrasound Ablation (TULSA) of Localized Prostate Cancer: A prospective Trial

🔍 **Clinical Question:**
Is the TULSA-PRO device safe and effective in treating organ-confined low-risk to intermediate-risk prostate cancer (PCa)

💡 **Key Insight:**
After 12 months, 43.5% of patients still had a biopsy-detectable cancerous tumor. However, there was a 40% recurrence-free rate and a 72% treatment-free survival rate at a median follow-up of 37 months.
Urinary and sexual dysfunction was common, with 26% developing stress incontinence, 35% developing overactive bladder, and 54% of potent patients developing erectile dysfunction.

👉 **Why it matters:**
The TULSA-PRO device shows promising results for the focal treatment of localized prostate cancer, although it is not universally curative and was associated with urinary and sexual functional deficits.

➡️ **Full Article:** https://brnw.ch/21wVBIy

09/03/2025

**NEW IN JVIR:** Histopathologic Response and Oncologic Outcomes after Segmental and Subsegmental Transarterial Chemoembolization and Radioembolization for Hepatocellular Carcinoma

🔍 **Clinical Question:**
Does segmental/subsegmental transarterial chemoembolization (TACE) or transarterial radioembolization (TARE) provide better histopathologic outcome in patients with hepatocellular carcinoma?

💡 **Key Insight:**
Transarterial radioembolization was superior to transarterial chemoembolization in achieving complete pathologic necrosis (CPN), both before and after propensity score matching.

The positive predictive values of a lesion having complete pathologic necrosis given complete radiologic response before transplant were 42.9% for transarterial chemoembolization and 89.0% for transarterial radioembolization.

👉 **Why it matters:**
TARE was superior to TACE in achieving pathologic necrosis, which translated into improved recurrence-free survival.

➡️ **Full Article:** https://brnw.ch/21wVqOw

08/25/2025

**NEW IN JVIR:** Transarterial Embolization for Pulmonary Arteriovenous Malformation: A Systematic Review and Meta-Analysis

🔍 **Clinical Question:**
Does an updated meta-analysis continue to show that transcatheter embolization for treatment of pulmonary arteriovenous malformations (PAVMs) is safe and effective? What additional insights does it offer?

💡 **Key Insight:**
Transcatheter embolization for pulmonary arteriovenous malformations demonstrated a high technical success rate (>98%), whereas the reported rate of postembolization catastrophic events was low (1.0%).

The use of vascular plugs was associated with significantly lower persistence rates than coils only (13.6% vs 32.7%).
Venous sac embolization showed a markedly lower persistence rate than feeding artery embolization (3.8% vs 24.3%).

👉 **Why it matters:**
PAVM embolization, especially using vascular plugs and encompassing venous sac embolization, has favorable technical and treatment success rates and low risk of severe AEs.

➡️ **Full Article:** https://brnw.ch/21wVb5A

-Analysis

08/22/2025

Trainees in can take advantage of the Journal of Vascular and Interventional Radiology (JVIR) Resident Editorial Fellowship to improve review skills. This offers a great opportunity to gain leadership experience, manage a capstone project, and receive mentoring. Apply by Oct. 10! https://brnw.ch/21wV7hs

08/21/2025

**NEW IN JVIR:** Transperineal MR Imaging–Guided Prostate Biopsy: A Prospective Randomized Controlled Study on Safety and Effectiveness Compared with Transrectal Biopsy

🔍 **Clinical Question:**
Is magnetic resonance (MR) imaging–guided in-bore transperineal prostate biopsies (TP-Bx) safe and tolerable?

💡 **Key Insight:**
Adverse events occurred in 8.9% of patients undergoing transrectal prostate biopsy and 4.4% of patients undergoing transperineal prostate biopsy, with no significant difference between groups. Transperineal approach demonstrated a higher cancer detection rate (42.5%) than transrectal approach (28.2%) and a significantly higher clinically significant cancer detection rate (27.5% vs 7.7%, P = .019).

Quality-of-life and pain assessments showed no significant differences between groups, although changes in management were more frequent following transperineal prostate biopsy (32.5% vs 15.4%, P = .050).

👉 **Why it matters:**
MR imaging–guided transperineal prostate biopsy is a safe and effective procedure with an enhanced detection rate in non–biopsy-naïve patients, with significant impact on clinical management strategies.

➡️ **Full Article:** https://brnw.ch/21wV5K8

08/13/2025

🚨 Calling all future leaders in IR!�
📚 Join the JVIR Trainee Reviewer Workshop and gain insider skills in peer review, critical appraisal, and academic publishing.�
💡 Learn directly from JVIR editors—sharpen your scholarly voice and contribute to the future of IR.

🔗 Register now: https://brnw.ch/21wUSRL

08/08/2025

🚨 Calling all future leaders in IR!�
📚 Join the JVIR Trainee Reviewer Workshop and gain insider skills in peer review, critical appraisal, and academic publishing.�
💡 Learn directly from JVIR editors—sharpen your scholarly voice and contribute to the future of IR.

🔗 Register now: https://brnw.ch/21wULYV

08/05/2025

**NEW IN JVIR:** The Impact of Chronic Kidney Disease on Amputation and Death Rates in Patients with Peripheral Artery Disease in the United States

🔍 **Clinical Question:**
Does chronic kidney disease (CKD) affect the incidence of amputation and death among patients with peripheral artery disease (PAD) in the United States?

💡 **Key Insight:**
Patients with peripheral artery disease (PAD) with chronic kidney disease (CKD) Stage 5 had 4 times higher amputation rates (31.3% vs 7.8%) and 5 times higher mortality (4.7% vs 0.9%) than those with PAD without CKD.

Patients with PAD, CKD Stage 5, and diabetes had an amputation rate of 36.5%.

Patients with PAD on dialysis showed significantly higher estimates for amputation and death compared with patients with PAD not on dialysis.

👉 **Why it matters:**
Diabetes tripled the amputation rate in patients with PAD and CKD Stages 1–4 (26.1% vs 8.7%) and doubled the amputation rate in those with PAD and CKD Stage 5 (36.5% vs 15.9%).

➡️ **Full Article:** https://brnw.ch/21wUGmr

07/31/2025

**NEW IN JVIR:** Magnetic Resonance–Digital Subtraction Angiography as a Preprocedural Imaging Modality before Transcatheter Arterial Microembolization for Chronic Musculoskeletal Pain

🔍 **Clinical Question:**
Can magnetic resonance (MR)–digital subtraction angiography (DSA) replace conventional DSA as a preprocedural imaging modality for transcatheter arterial microembolization (TAME) in musculoskeletal pain management?

💡 **Key Insight:**
Magnetic resonance (MR)–digital subtraction angiography (DSA) demonstrated high sensitivity (1.0) and substantial interobserver agreement (κ = 0.73) for detecting abnormal enhancement in musculoskeletal pain management.

All abnormal enhancement observed in conventional DSA were also detected by MR-DSA, indicating its potential as a standard imaging modality for preprocedural evaluations.

👉 **Why it matters:**
MR-DSA can serve as a less invasive alternative to DSA for preprocedural assessment in transcatheter arterial microembolization procedures.

➡️ **Full Article:** https://brnw.ch/21wUz2c

07/29/2025

The call for abstracts for the SIR 2026 Annual Scientific Meeting is now open!

Abstract presenters are encouraged to submit full manuscripts to JVIR for publication consideration. Co–Editors-in-Chiefs Charles E. Ray Jr., MD, PhD, FSIR, and Brian F. Funaki, MD, FSIR, in collaboration with the SIR Annual Meeting Committee, invite you to build on your 2026 abstract and reach a broader audience through JVIR.

Accepted JVIR manuscripts gain extended visibility via SIR and JVIR channels, including visual and audio abstracts, social media promotion, the JVIR blog, and more.
https://brnw.ch/21wUvE0

07/23/2025

**NEW IN JVIR:** The Impact of Chronic Kidney Disease on Amputation and Death Rates in Patients with Peripheral Artery Disease in the United States

🔍 **Clinical Question:**

Does chronic kidney disease (CKD) affect the incidence of amputation and death among patients with peripheral artery disease (PAD) in the United States?

💡 **Key Insight:**

Patients with peripheral artery disease (PAD) with chronic kidney disease (CKD) Stage 5 had 4 times higher amputation rates (31.3% vs 7.8%) and 5 times higher mortality (4.7% vs 0.9%) than those with PAD without CKD.

Patients with PAD, CKD Stage 5, and diabetes had an amputation rate of 36.5%.

Patients with PAD on dialysis showed significantly higher estimates for amputation and death compared with patients with PAD not on dialysis.

👉 **Why it matters:**

Diabetes tripled the amputation rate in patients with PAD and CKD Stages 1–4 (26.1% vs 8.7%) and doubled the amputation rate in those with PAD and CKD Stage 5 (36.5% vs 15.9%).

➡️ **Full Article:** https://www.jvir.org/article/S1051-0443(25)00250-7/fulltext

07/16/2025

Magnetic Resonance–Digital Subtraction Angiography as a Preprocedural Imaging Modality before Transcatheter Arterial Microembolization for Chronic Musculoskeletal Pain

https://www.jvir.org/article/S1051-0443(25)00245-3/fulltext

Journal of Vascular and Interventional Radiology

09/09/2025

09/03/2025

08/25/2025

08/22/2025

08/21/2025

08/13/2025

08/08/2025

08/05/2025

07/31/2025

07/29/2025

07/23/2025

07/16/2025

Address

Telephone

Website

Alerts

Shortcuts

Share